13/07/2018 01:10:58

Spero Therapeutics Announces Pricing of Securities Offering

CAMBRIDGE, Mass., July 12, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, today announced the pricing of an underwritten public offering of 3,780,000 shares of its common stock and 2,220 shares of its non-voting Series A Convertible Preferred Stock.  The public offering price of each share of common stock is $12.50 and the public offering price of each share of Series A Preferred Stock is $12,500.00.

The gross proceeds to Spero from this offering are $75,000,000, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Spero. All of the shares in the offering will be sold by Spero.  In addition, Spero has granted the underwriters a 30-day option to purchase up to an additional 567,000 shares of common stock at the public offering price, less the underwriting discount.  The offering is expected to close on July 17, 2018, subject to customary closing conditions.

Each share of Series A Preferred Stock is convertible into 1,000 shares of common stock, provided that conversion will be prohibited if, as a result, the holder of the Series A Preferred Stock and its affiliates would own more than 9.99% of the total number of shares of common stock then outstanding.

Cowen and Company, LLC, Stifel, Nicolaus & Company, Incorporated and Cantor Fitzgerald & Co. are serving as joint book-running managers for the offering.  Oppenheimer & Co. Inc. is acting as lead manager for the offering, and H.C. Wainwright & Co., LLC is acting as co-manager for the offering.

A registration statement relating to the offering has been filed with the Securities and Exchange Commission (SEC) and was declared effective on July 12, 2018.  The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, from Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (631) 274-2806; from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720, or by email at syndprospectus@stifel.com; or from Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, NY 10022, or by email at prospectus@cantor.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Spero

Spero is a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections.

Forward-Looking Statements

Investors are cautioned that statements in this press release regarding the intention, completion, timing and option relating to the proposed public offering constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the proposed public offering. There can be no assurance that Spero will be able to complete the proposed public offering. Additional information on risks facing Spero can be found under the heading “Risk Factors” in Spero’s periodic reports, including its annual report on Form 10-K and quarterly reports on Form 10-Q, and in the preliminary prospectus related to this offering filed with the SEC, and the final prospectus related to this offering to be filed with the SEC, each available on the SEC's web site at www.sec.gov. Spero expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Spero Investor Contact:

Sharon Klahre

Director, Investor Relations

857-242-1547

IR@sperotherapeutics.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
19 Sep
 
Jeg har været med som skribent her på EI siden 2012 og jeg har haft mange gode øjeblikke ved at være..
62
20 Sep
VWS
Vestas aktien fylder en del i min portefølje, hvorfor jeg følger den tæt. Jeg var dog selv tidligere..
35
22 Sep
DANSKE
Er det ikke tænkevækkende i disse dage at være vidne til vores politikere, der berettiget forarges o..
31
20 Sep
 
Danmark forærer 12mia kr væk til svindlere - med hjælp fra et par fordrukne ansatte i skat. Så stort..
23
23 Sep
DANSKE
Danske har intet lært. Ikke af finanskrisen, ikke af skattely sager, ikke af panama sager. De har ty..
22
24 Sep
TEVA
Dansk Aktionaerforening gjorde et lille scoop og fik Kaare Schultz til at deltage i InvestorDagen i ..
19
24 Sep
VWS
MHI Vestas turbine platform can scale up to GE's 12 MW rival: CEO https://www.reuters.com/article/us..
18
15:57
DANSKE
Danske Bank sagen er ganske enkelt - gå efter bolden: 1. Den estiske afdeling af Danske Bank har for..
16
20 Sep
DANSKE
Erhversministeren mener at hvidvaskskandalen er "en af de største skandaler i danmarkshistorien" og ..
16
21 Sep
DANSKE
Desværre har pressen og visse politikere dømt i en sag for at mele deres kager.  Hvis man har fulgt ..
14

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Viracta Announces Scientific Advisory Board Formation
2
Payment Security Compliance drops for the first time in six years, states Verizon’s 2018 Payment Security Report
3
PCG Advisory Group Co-Sponsored Family Office Event Presented by Morgan Creek Capital and BlockWorks Group
4
Motif Bio Reports Half-Year 2018 Financial Results and Operational Progress
5
Recall Studios Will Host Shareholder Call, Tuesday, September 25th at 11am EST

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
25 September 2018 20:49:01
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180919.1 - EUROWEB2 - 2018-09-25 21:49:01 - 2018-09-25 20:49:01 - 1000 - Website: OKAY